AtriCure, Inc.
ATRC Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 23, 2026
$58.97
KIRA · Stoqly’s AI analyst, in plain words
- AtriCure, Inc. had $535M of revenue in fiscal 2025, up 14.9% on the year before. Over five years, revenue changed +20.9% a year on average.
- Its operating margin was −1.8%, up 6.8 pts: of every 100 in sales, about −2 is left after running the business.
- AtriCure, Inc. lost $11.4M in fiscal 2025.
- Free cash flow was $48.3M in fiscal 2025, 9.0% of revenue.
- AtriCure, Inc. has $98.3M more cash than debt.
Market cap
$2.9B
P/E
—
Revenue
$535M
Net income
−$11.4M
Free cash flow
$48.3M
Operating margin
−1.8%
AtriCure, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+14.9%
Yes. Sales grew 14.9% last year.
Does it make a profit?
−2.1%
No. It lost money last year.
Does profit turn into cash?
9.0%
Partly. 9.0% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
7 / 9
Solid. It passes 7 of 9 health tests.
What AtriCure, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 19, 2026
- Legal name
- AtriCure, Inc.
- CIK
- 0001323885
AtriCure, Inc. · ATRC
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $274M | $330M | $399M | $465M | $535M |
| Revenue growth | 32.8% | 20.4% | 20.8% | 16.5% | 14.9% |
| Gross margin | 75.0% | 74.4% | 75.2% | 74.7% | 75.0% |
| Operating margin | 20.1% | −12.9% | −6.7% | −8.6% | −1.8% |
| Net income | $50.2M | −$46.5M | −$30.4M | −$44.7M | −$11.4M |
| Net margin | 18.3% | −14.1% | −7.6% | −9.6% | −2.1% |
| Diluted EPS | $1.09 | −$1.02 | −$0.66 | −$0.95 | −$0.24 |
| Cash | |||||
| Cash from operations | −$13.8M | −$22.1M | $4.5M | $12.2M | $57.3M |
| Capital expenditure | $9.8M | $16.9M | $12.0M | $11.5M | $9.1M |
| Free cash flow | −$23.5M | −$39.0M | −$7.5M | $0.7M | $48.3M |
| FCF margin | −8.6% | −11.8% | −1.9% | 0.2% | 9.0% |
| Share count change | 9.3% | −0.6% | 1.2% | 1.4% | 1.7% |
| Debt and strength | |||||
| Cash and short-term investments | $119M | $121M | $137M | $123M | $167M |
| Debt incl. finance leases | $71.0M | $70.1M | $70.1M | $73.1M | $69.1M |
| Shareholders' equity | $484M | $457M | $466M | $461M | $492M |
| Net debt / EBITDA | −0.8x | — | — | — | −37.2x |
| Current ratio | 3.5x | 3.7x | 3.6x | 3.6x | 4.0x |
| Interest coverage | 11.2x | −8.6x | −3.9x | −6.2x | −1.6x |
| Returns and quality | |||||
| Return on capital | 13.0% | −8.5% | −5.4% | −7.8% | −1.9% |
| Return on equity | 11.2% | −9.9% | −6.6% | −9.6% | −2.4% |
| Return on tangible equity | 24.4% | −25.4% | −18.2% | −26.3% | −5.5% |
| Piotroski F-score | 4 | 4 | 6 | 4 | 7 |
| Altman Z'' | 4.5 | 3.2 | 3.2 | 2.8 | 3.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$4.4M
8 insiders
Of sales under plans
20%
$0.9M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
AtriCure, Inc. · ATRC
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $58.97 a share, the company is worth $2.9B.
Source: SEC EDGAR XBRL filings (CIK 0001323885). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.